PHiD-CV effectiveness against invasive pneumococcal disease caused by serotype 19A

Vaccine. 2015 Jan 9;33(3):415. doi: 10.1016/j.vaccine.2014.10.056. Epub 2014 Nov 3.

Authors

Marta Moreira¹, Javier Nieto Guevara², Diana Caceres³

Affiliations

¹ GSK Vaccines, Avenue Fleming 20, 1300 Wavre, Belgium. Electronic address: marta.x.moreira@gsk.com.
² GSK Vaccines Clayton, City of Knowledge, Bldg. 230, Panama.
³ GSK, Av. El Dorado No. 69B-45, Piso 9, Corporate Center, Bogota, Colombia.

PMID: 25444809
DOI: 10.1016/j.vaccine.2014.10.056

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Penicillin Resistance*
Pneumococcal Infections / microbiology*
Streptococcus pneumoniae / classification*